About: Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

scientific article (publication date: 9 June 2001)

Attributes	Values
rdf:type	Item
description	artículu científicu espublizáu en 2001 (ast) vědecký článek publikovaný v roce 2001 (cs) 2001 թվականի հունիսին հրատարակված գիտական հոդված (hy) наукова стаття, опублікована в червні 2001 (uk) 2001 թուականի Յունիսին հրատարակուած գիտական յօդուած (hyw) ശാസ്ത്രപ്രബന്ധം (ml) im Juni 2001 veröffentlichter wissenschaftlicher Artikel (de) article publié dans la revue scientifique The Lancet (fr) vedecký článok (publikovaný 2001/06/09) (sk) wetenschappelijk artikel (gepubliceerd op 2001/06/09) (nl) مقالة علمية (نشرت في 9-6-2001) (ar) scientific article (publication date: 9 June 2001) (en)
publication date	wds:Q28202251-4E3FED70-0329-428B-AA72-F76C18B0758E
publication date	2001-06-09 00:00:00Z (xsd:dateTime)
language of work or name	wds:Q28202251-5705364D-8C95-4366-9D14-36EBA03DC60B
language of work or name	English
cites work	wds:Q28202251-09F0383C-0667-42B5-9962-FFB4657BF1E5 wds:Q28202251-19098D51-8C62-47C5-B788-D3EA64907B86 wds:Q28202251-1AB385D8-F9C7-4635-ABD7-A0224704C8F8 wds:Q28202251-1FD959CB-595D-4B3A-AF27-A9E07F001A47 wds:Q28202251-242F2B02-2E7F-4A0A-80F6-1AFBA3DF5E03 wds:Q28202251-263AA9F3-93EE-4DA6-A553-5F19BC626BA9 wds:Q28202251-37748B8B-136F-406E-9D36-D1E7D1BE2ACC wds:Q28202251-3D0805BA-5071-4A6D-9692-547C0B5AD02C wds:Q28202251-4A20B420-5B7C-4AE9-9CC8-C3BCACC8181A wds:Q28202251-5B8E79DE-04C6-4780-91A2-09B5B4506608 wds:Q28202251-5ED15BB6-A7DB-46A6-AC70-745A6AD9E1E3 wds:Q28202251-63346FCA-BE60-4145-BB4B-ED6D977726BA wds:Q28202251-67A72431-13CF-461C-A7F5-64FFE8432979 wds:Q28202251-6DC54920-B11D-4235-B498-08231BDE7CC8 wds:Q28202251-789D527A-D517-4AB0-BFEF-D8F9DE9224EE wds:Q28202251-A6531F8D-3954-49C8-9BC0-2962C0701099 wds:Q28202251-AA165169-C4CD-4B6B-8E6B-F5847E9AA181 wds:Q28202251-B2FC896E-7747-45CA-9064-5557DBEABE07 wds:Q28202251-B7707D31-BCE9-4D75-94A6-A804ED9B7000 wds:Q28202251-BC782F95-3775-4AC6-AAF1-B00FF71B94F4 wds:Q28202251-C3D4D617-0BE8-486C-BCB5-BE43A282784C wds:Q28202251-DAABDEFA-2F44-4EC1-B9B2-96B31112269A wds:Q28202251-EEA71C6D-038B-4DF4-B5F8-8579384C0BCC wds:Q28202251-F7A3BBC6-EDDD-4E38-989B-9B45260CADDA
cites work	The pathogenesis of psoriasis: immunological facts and speculations Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial Nuclear factor-kappaB: a pivotal transcription factor in chronic inflammatory diseases Reduction of chemokine levels and leukocyte traffic to joints by tumor necrosis factor alpha blockade in patients with rheumatoid arthritis Chimeric anti-TNF-alpha monoclonal antibody cA2 binds recombinant transmembrane TNF-alpha and activates immune effector functions Tumor necrosis factor alpha antibody (infliximab) therapy profoundly down-regulates the inflammation in Crohn's ileocolitis. Cyclosporine for plaque-type psoriasis. Results of a multidose, double-blind trial IL-10 is a key cytokine in psoriasis. Proof of principle by IL-10 therapy: a new therapeutic approach Aetiology and pathogenesis of psoriasis Construction and initial characterization of a mouse-human chimeric anti-TNF antibody Effects of administration of a single dose of a humanized monoclonal antibody to CD11a on the immunobiology and clinical activity of psoriasis The immunology of psoriasis Severe Psoriasis – Oral Therapy with a New Retinoid Treatment of psoriasis Decrease in cellularity and expression of adhesion molecules by anti-tumor necrosis factor alpha monoclonal antibody treatment in patients with rheumatoid arthritis Blockade of T lymphocyte costimulation with cytotoxic T lymphocyte-associated antigen 4-immunoglobulin (CTLA4Ig) reverses the cellular pathology of psoriatic plaques, including the activation of keratinocytes, dendritic cells, and endothelial cells Elevated tumour necrosis factor-alpha (TNF-alpha) biological activity in psoriatic skin lesions The economic impact of psoriasis increases with psoriasis severity. Tumor necrosis factor Successful in vivo blockade of CD25 (high-affinity interleukin 2 receptor) on T cells by administration of humanized anti-Tac antibody to patients with psoriasis Treatment with anti-tumor necrosis factor alpha (TNF-alpha) monoclonal antibody dramatically decreases the clinical activity of psoriasis lesions Cytokines and chemokines in the initiation and regulation of epidermal Langerhans cell mobilization Psoriasis. Immunopathology and immunomodulation Immunopathogenesis of psoriasis. The road from bench to bedside is a 2-way street
author name string	wds:Q28202251-054A9D19-B34E-45B6-87E1-30CB91607CE0 wds:Q28202251-A36AC9F7-17B8-4C5B-9943-A1A4605C1FB8 wds:Q28202251-BBC1DE5F-E1BE-4179-BF86-42117D61FC6A wds:Q28202251-D36F25FB-C275-4E0F-9043-6039E5E0CABB wds:Q28202251-DAC543BF-B3FD-48E3-814A-36C8818CF568 wds:Q28202251-E6A1704F-4802-417B-9EA7-62E75AE7E3DE
OpenCitations bibliographic resource ID	wds:Q28202251-EC843763-4A4D-4671-87D1-E7C26426D784
OpenCitations bibliographic resource ID	https://w3id.org/oc/corpus/br/1918811
author name string	P Romano A B Gottlieb L T Dooley D G Baker U Chaudhari L D Mulcahy
OpenCitations bibliographic resource ID	1918811
rdfs:label	Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial (en) Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial (nl) Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial (ast)
skos:prefLabel	Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial (en) Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial (nl) Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial (ast)
name	Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial (en) Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial (nl) Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial (ast)
title	wds:Q28202251-281B09C8-21C2-4D11-89C3-C4DAAA1A533E
title	Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial (en)
page(s)	wds:Q28202251-78A869FD-B3EB-4BB7-A817-62CF8ED222DB
page(s)	1842-7
instance of	wds:Q28202251-48E59F8C-CD27-41C2-82F4-CA87C1C50B5E
instance of	scholarly article
uses	wds:Q28202251-44CE236F-A83F-4FAB-BDA3-7D8EF8089F25
uses	randomized experiment
PubMed ID	wds:Q28202251-14F2FE66-4ADE-438E-BBC0-3FF2B17E574B
PubMed ID	http://rdf.ncbi.nlm.nih.gov/pubchem/reference/11410193
PubMed ID	11410193

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 188 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software